Insulin treatment in diabetic pregnancy

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue SUPPL. 2, 2008, Pages

  Mathiesen, Elisabeth R ^a   Vaz, Julius Anthony ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Novo Nordisk Pharma Singapore Pte Ltd   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; GLIBENCLAMIDE; GLUCAGON; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SOMATOMEDIN C;

ADVERSE OUTCOME; ANTIBODY RESPONSE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CALORIC INTAKE; CARBOHYDRATE INTAKE; CLINICAL TRIAL; CONGENITAL DISORDER; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; EXERCISE; FETUS WASTAGE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; LABOR; LACTATION; LIFESTYLE; MACROSOMIA; MATERNAL MORTALITY; MATERNAL NUTRITION; MORNING DOSAGE; NEWBORN MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PERINATAL DEATH; PLACENTAL TRANSFER; POSTPRANDIAL STATE; PRECONCEPTIONAL COUNSELING; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; SELF MONITORING;

EID: 44949186630     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.876     Document Type: Review

References (137)

1. Diabetes care and research in Europe: the St Vincent declaration. Diabet Med 1990; 7: 360.
2. Confidential Enquiry into Maternal and Child Health. Diabetes in Pregnancy: Are We Providing the Best Care? Findings of a National Enquiry. CEMACH: London, 2007.
3. Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care 2004; 27: 2819-2823.
4. Evers IM, de Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 2004; 328: 915.
5. Diabetes and pregnancy group, France. French multi-centric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2003; 26: 2990-2993.
6. Hawthorne G, Robson S, Ryall EA, et al. Prospective population based survey of outcome of pregnancy in diabetic women: results of the Northern Diabetic Pregnancy Audit, 1994. BMJ 1997; 315: 279-281.
7. Penney GC, Mair G, Pearson DWM, et al. Outcomes of pregnancies in women with type 1 diabetes in Scotland: a national population-based study. Br J Obstet Gynaecol 2003; 110: 315-318.
8. Casson IF, Clarke CA, Howard CV, et al. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ 1997; 315: 275-278.
9. Yang J, Cummings EA, O'Connell C, et al. Fetal and neo-natal outcomes of diabetic pregnancies. Obstet Gynecol 2006; 108: 644-650.
10. Macintosh MCM, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales and Northern Ireland: population based study. BMJ 2006; 333: 177-180.
11. Dunne F. Type 2 diabetes and pregnancy. Semin Fetal Neonatal Med 2005; 10: 333-339.
12. Clausen TD, Mathiesen E, Ekbom P, et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005; 28: 323-328.
13. Confidential Enquiry into Maternal and Child Health. Pregnancy in Women with Type 1 and Type 2 Diabetes 2002-2003, England, Wales and Northern Ireland. CEMACH: London, 2005.
14. Department of Health. National Service Framework for Diabetes: Standards. Department of Health: London, 2001.
15. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 2477-2486.
16. Platt MJ, Stanisstreet M, Casson IF, et al. St Vincent's declaration 10 years on: outcomes of diabetic pregnancies. Diabet Med 2002; 19: 216-220.
17. 1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care 2006; 29: 2612-2616.
18. Wender-Ozegowska E, Wroblewska K, Zawiejska A, et al. Threshold values of maternal blood glucose in early diabetic pregnancy - prediction of fetal malformations. Acta Obstet Gynecol Scand 2005; 84: 17-25.
19. Stotland NE, Caughey AB, Breed EM, et al. Risk factors and obstetric complications associated with macrosomia. Int J Gynecol Obstet 2004; 87: 220-226.
20. Leinonen PJ, Hiilesmaa VK, Kaaja RJ, et al. Maternal mortality in type 1 diabetes (in Danish). Diabetes Care 2001; 24: 1501-1502.
21. Evers IM, Edith WMT, De Valk HW, et al. Risk indicators predictive for severe hypoglycemia during the first trimester of type 1 diabetic pregnancy. Diabetes Care 2002; 25: 554-559.
22. Rosenn BM, Miodovnik M, Holcberg G, et al. Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstet Gynecol 1995; 85: 417-422.
23. Kimmerle R, Heinemann L, Delecki A, et al. Severe hypoglycemia incidence and predisposing factors in 85 pregnancies of type 1 diabetic women. Diabetes Care 1992; 15: 1034-1037.
24. The Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the diabetes control and complications trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
25. Mills JL, Knopp RH, Simpson JL, et al. Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. N Engl J Med 1988; 318: 671-676.
26. Inkster ME, Fahey TP, Dorman PT, et al. Poor glycated haernoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: systematic review of observational studies. BMC Pregnancy and Childbirth 2006; 6: 30.
27. Mills JL, Simpson JL, Driscoll SG, et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med 1988; 319: 1617-1623.
28. Kernaghan D, Penney GC, Pearson DW, et al. Birth weight and maternal glycated haemoglobin in pregnancies complicated by type 1 diabetes. Scott Med J 2007; 52: 9-12.
29. Hiilesmaa V, Suhonen L, Teramo K. Glycemic control is associated with pre-eclampsia but not with pregnancy-induced hypertension in women with type 1 diabetes mellitus. Diabetologia 2000; 43: 1534-1539.
30. Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes. Glycemic control prevents congenital abnormalities. JAMA 1991; 265: 731-736.
31. American Diabetes Association. Position statement on gestational diabetes mellitus. Diabetes Care 1986; 9: 430-431.
32. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. World Health Organization: Geneva, 1999.
33. Jensen DM, Damm P, Sorensen B, et al. Proposed diagnostic thresholds for gestational diabetes mellitus according to a 75-g oral glucose tolerance test. Maternal and perinatal outcomes in 3260 Danish women. Diabet Med 2003; 20: 51-57.
34. O'Sullivan JB. The Boston gestational diabetes studies. In Carbohydrate Metabolism in Pregnancy and the Newborn, Sutherland HW, Stowers JM, Pearson DWM (eds). Springer-Verlag: London, 1989; 287-294.
35. Gonzalez-Quintero VH, Istwan NB, Rhea DJ, et al. The impact of glycemic control on neonatal outcome in singleton pregnancies complicated by gestational diabetes. Diabetes Care 2007; 30: 467-470.
36. Reece EA, Homko C, Wiznitzer A. Metabolic changes in diabetic and nondiabetic subjects during pregnancy. Obstet Gynecol Surv 1994; 49: 64-71.
37. Gunderson EP. Gestational diabetes and nutritional recommendations. Curr Diab Rep 2004; 4: 377-386.
38. Turok DK, Ratcliffe SD, Baxley EG. Management of gestational diabetes mellitus. Am Fam Physician 2003; 68: 1767-1772.
39. Wilson RD, Davies G, Desilets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003; 25: 959-973.
40. American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care 2004; 27(Suppl 1): S36-S46.
41. Jovanovic-Peterson L, Peterson CM. Exercise and the nutritional management of diabetes during pregnancy. Obstet Gynecol Clin North Am 1996; 23: 75-86.
42. Langer O, Anyaegbunam A, Brustman L, et al. Management of women with one abnormal oral glucose tolerance test value reduces advers6 outcome in pregnancy. Am J Obstet Gynecol 1989; 161: 593-599.
43. Reader D, Splett P, Gunderson EP. Impact of gestational diabetes mellitus nutrition practice guidelines implemented by registered dietitians on pregnancy outcomes. J Am Diet Assoc 2006; 106: 1426-1433.
44. Harris GD, White RD. Diabetes management and exercise in pregnant patients with diabetes. Clin Diab 2005; 23: 165-168.
45. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989; 161: 415-419.
46. Bung P, Artal R, Khodiguian N, et al. Exorcise in gestational diabetes. An optional therapeutic approach? Diabetes 1991; 40(Suppl 2): 182-185.
47. Avery MD, Leon AS, Kopher RA. Effects of a partially home-based exercise program for women with gestational diabetes. Obstet Gynecol 1997; 89: 10-15.
48. Brankston GN, Mitchell BF, Ryan EA, et al. Resistance exercise decreases the need for insulin in overweight women with gestational diabetes mellitus. Am J Obstet Gynecol 2004; 190: 188-193.
49. Joint Formulary Committee. British National Formulary (edn 52). British Medical Association and Royal Pharmaceutical Society of Great Britain: London, September 2006.
50. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134-1138.
51. Ekpebegh CO, Coetzee EJ, van der Merwe L, et al. A 10-year retrospective analysis of pregnancy outcome in pregestational type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med 2007; 24: 253-258.
52. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17: 507-511.
53. Homko CJ, Sivan E, Reece AE. Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes during pregnancy? Treat Endocrinol 2004; 3: 133-139.
54. Nielsen LR, Pedersen-Bjeregaard U, Thorsteinsson B, et al. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care 2008; 31: 9-14.
55. 1c levels and the self-monitoring of blood glucose levels adequately reflect glycaemic control during pregnancy in women with type 1 diabetes mellitus? Diabetologia 2006; 49: 25-28.
56. Schrot RJ. Targeting plasma glucose: preprandial versus postprandial. Clin Diab 2004; 22: 169-172.
57. De Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333: 1237-1241.
58. Manderson JG, Patterson CC, Hadden DR, et al. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003; 189: 507-512.
59. Jovanovic-Peterson L, Peterson CM, Reed GF, et al. Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 1991; 164: 103-111.
60. Combs CA, Gunderson E, Kitzmiller JL, et al. Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care 1992; 15: 1251-1257.
61. El-Halwagy HE, Gelbaya TA, El-wahab MF, et al. The mean third trimester postprandial blood glucose of diabetic pregnant patients and infant birth weight in the Kuwaiti population. Medscape General Medicine 2001; 3(4).
62. Ben-Haroush A, Yogev Y, Chen R, et al. The postprandial glucose profile in the diabetic pregnancy. Am J Obstet Gynecol 2004; 191: 576-581.
63. Lawson PM, Champion MC, Canny C, et al. Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and preproliferative retinopathy. Br J Ophthalmol 1982; 66: 762-766.
64. The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 1984; 311: 365-372.
65. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
66. Henricsson M, Nilsson A, Janzon L, et al. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 123-131.
67. Grunwald JE, Riva CE, Martin DB, et al. Effect of an insulin-induced decrease in blood glucose on the human diabetic retinal circulation. Ophthalmology 1987; 94: 1614-1620.
68. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82: 725-730.
69. Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282-291.
70. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy: the Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18: 631-637.
71. Buchanan TA, Schemmer JK, Freinkel N. Embryotoxic effects of brief maternal insulin-hypoglycemia during organogenesis in the rat. J Clin Invest 1986; 78: 643-649.
72. Smoak IW, Sadler TW. Embryonic effects of short-term exposure to hypoglycemia in mouse embryos in vitro. Am J Obstet Gynecol 1990; 163: 619-624.
73. Bauman WA, Yalow RS. Transplacental passage of insulin complexed to antibody. Proc Natl Acad Sci U S A 1981; 78: 4588-4590.
74. Menon RK, Cohen RM, Sperling MA, et al. Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus: its role in fetal macrosomia. N Engl J Med 1990; 323: 309-315.
75. Jovanovic-Peterson L, Kitzmiller JL, Peterson CM. Randomized trial of human versus animal species insulin in diabetic pregnant women: improved glycemic control, not fewer antibodies to insulin, influences birth weight. Am J Obstet Gynecol 1992; 167: 1325-1330.
76. McCance D, Damm P, Mathiesen E, et al. No increase in insulin antibodies and no clear evidence of transfer of insulin aspart across the placenta in pregnant women with type 1 diabetes. Diabetes 2007; 56(Suppl 1): A22.
77. Nachum Z, Ben-Shlomo I, Weiner E, et al. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ 1999; 319: 1223-1227.
78. Roy B, Chou MC, Field JB. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. J Clin Endocrinol Metab 1980; 50: 475-479.
79. Brange J, Owens DR, Kang S, et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
80. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
81. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin. Diabetes Care 1999; 22: 1501-1506.
82. Dailey G, Rosenstock J, Moses RG, et al. Insulin glulisine produces improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
83. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22(Suppl 2): B109-B113.
84. Heinemann L, Linkeschova R, Rave Y, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-649.
85. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-643.
86. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obesity 2004; 28(Suppl 2): S23-S28.
87. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.
88. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659.
89. Heise T, Nosek L, Biilmann Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
90. Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006; 23: 729-735.
91. Roach P, Yue L, Arora V, et al. Improved postprandial. glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258-1261.
92. Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.
93. Lapolla A, Dalfra MG, Fedele D. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? Diabetes Metab Res Rev 2005; 21: 241-252.
94. Home PD, Lindholm A, Riis A, for the European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000; 17: 762-770.
95. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588.
96. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004; 21: 769-775.
97. Simpson D, McCormack PL, Keating GM, et al. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs 2007; 67: 407-434.
98. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007; 77: 1-15.
99. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
100. Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005; 28: 10-14.
101. Jovanovic L, Ilic S, Pettitt DJ, et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22: 1422-1427.
102. Bhattacharyya S, Brown S, Hughes S, et al. Insulin lispro and regular human insulin in pregnancy. Q J Med 2001; 94: 255-260.
103. Persson B, Swahn ML, Hjertberg R, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 2002; 58: 115-121.
104. Diamond T, Kormas N. Possible adverse fetal effect of insulin lispro. N Engl J Med 1997; 337: 1009-1010.
105. Kitzmiller JL, Main E, Ward B, et al. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 1999; 22: 874-875.
106. Wyatt JW, Frias JL, Hoyme HE, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 2005; 22: 803-807.
107. Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771-776.
108. Hod M, Damin P, Kaaja R, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2007. DOI: 10.1016/j.ajog.2007.08.005.
109. Pettitt DJ, Ospina P, Kolaczynski JW, et al. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care 2003; 26: 183-186.
110. Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 2002; 25: 1095-1096.
111. Di Cianni G, Volpe L, Lencioni C, et al. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 2005; 28: 982-983.
112. Woolderink JM, van Loon AJ, Storms F, et al. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care 2005; 28: 2594-2595.
113. Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 2007; 114: 453-457.
114. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
115. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
116. Rayburn W, Piehl E, Lewis E, et al. Changes in insulin therapy during pregnancy. Am J Permatol 1985; 2: 271-275.
117. Langer O, Anyaegbunam A, Brustman L, et al. Pregestational diabetes: insulin requirements throughout pregnancy. Am J Obstet Gynecol 1988; 159: 616-621.
118. Jovanovic L, Knopp RH, Brown Z, et al. Declining insulin requirement in the late first trimester of diabetic pregnancy. Diabetes Care 2001; 24: 1130-1136.
119. Steel JM, Johnstone FD, Hume R, et al. Insulin requirements during pregnancy in women with type 1 diabetes. Obstet Gynecol 1994; 83: 253-258.
120. McManus RM, Ryan EA. insulin requirements in insulin-dependent and insulin-requiring GDM women during final month of pregnancy. Diabetes Care 1992; 15: 1323-1327.
121. Potter JM, Reckless JP, Cullen DR. Subcutaneous continuous insulin infusion and control of blood glucose concentration in diabetics in third trimester of pregnancy. BMJ 1980; 280: 1099-1101.
122. Carta Q, Meriggi E, Trossarelli GF, et al. Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabetes Metab 1986; 12: 121-129.
123. Gimenez M, Conget I, Nicolau J, et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol 2007; 44: 34-37.
124. Jovanovic L. Glucose and insulin requirements during labor and delivery: the case for normoglycemia in pregnancies complicated by diabetes. Endocr Pract 2004; 10 (Suppl 2): 40-45.
125. Jovanovic L, Peterson CM. Insulin and glucose requirements during the first stage of labor in insulin-dependent diabetic women. Am J Med 1983; 75: 607-612.
126. Njenga E, Lind T, Taylor R. Five year audit of peripartum blood glucose control in type 1 diabetic patients. Diabet Med 1992; 9: 567-570.
127. Lean ME, Pearson DW, Sutherland HW. Insulin management during labour and delivery in mothers with diabetes. Diabet Med 1990; 7: 162-164.
128. Caplan RH, Pagliara AS, Beguin EA, et al. Constant intravenous insulin infusion during labor and delivery in diabetes mellitus. Diabetes Care 1982; 5: 6-10.
129. Rosenberg VA, Eglinton GS, Rauch ER, et al. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol 2006; 195: 1095-1099.
130. Feldberg D, Dicker D, Samuel N, et al. Intrapartum management of insulin-dependent diabetes mellitus (IDDM) gestants. A comparative study of constant intravenous insulin infusion and continuous subcutaneous insulin infusion pump (CSIIP). Acta Obstet Gynecol Scand 1988; 67: 333-338.
131. Slocum J, Barcio L, Darany J, et al. Preconception to postpartum: management of pregnancy complicated by diabetes. Diabetes Educ 2004; 30: 740, 742-744, 747-753.
132. Stage E, Norgard H, Damm P, et al. Long-term breast-feeding in women with type 1 diabetes. Diabetes Care 2006; 29: 771-774.
133. Kjos SL, Henry O, Lee RM, et al. The effect of lactation on glucose and lipid metabolism in women with recent gestational diabetes. Obstet Gynecol 1993; 82: 451-455.
134. Pettitt Di, Knowler WC. Long-term effects of the intrauterine environment, birth weight, and breast-feeding in Pima Indians. Diabetes Care 1998; 21(Suppl. 2): B138-B141.
135. Feig DS, Briggs GG, Kraemer JM, et al. Transfer of glyburide and glipizide into breast milk. Diabetes Care 2005; 28: 1851-1855.
136. Jovanovic-Peterson L, Fuhrmann K, Hedden K, et al. Maternal milk and plasma glucose and insulin levels: studies in normal and diabetic subjects. J Am Coll Nutr 1989; 8: 125-131.
137. Novo Nordisk Ltd. Actrapid 100 IU/ml Solution for Injection in a Vial, 2004 (in Danish).